Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase
II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion
to Prevent Neovascular Glaucoma - the STRONG Study
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Gene Signal SAS
Collaborators:
Johannes Gutenberg University Mainz Moorfields Eye Hospital NHS Foundation Trust University Hospital of Cologne